Shots:
- The companies collaborated to commercialize the first biosimilar Darbepoetin alpha in the GCC market for the treatment of anemia associated with chronic renal failure. The CKD biosimilar is currently approved in South Korea
- The collaboration with CKD helps to build the biosimilar footprint in the Middle East and Africa markets to reach more people living with severe chronic diseases
- Menagen focuses to provide broad access to patients with unmet medical needs by utilizing its local expertise and capabilities and focus on various niche therapeutic products
Click here to read full press release/ article | Ref: Business Wire | Image: Business Wire
The post Menagen Signs a Commercialization Agreement with CKD for Biosimilar Darbepotein Alfa first appeared on PharmaShots.
